InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.46
(
0.09%
)
Bitcoin
61,056.75
(
-0.64%
)
Post# of 251799
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

turtlepower

Send PM Follow Ignore
Followers 1
Posts 1114
Boards Moderated 0
Alias Born 04/07/2009

turtlepower

Re: gfp927z post# 141740

Saturday, 05/12/2012 8:43:34 AM

Saturday, May 12, 2012 8:43:34 AM

Post# of 251799
PYMX - The presentation from May shows different numbers which don't seem too impressive.
http://files.shareholder.com/downloads/ABEA-4ITCYZ/1867411390x0x556268/4772089E-3CE5-4BCD-A950-AF3FC7098211/Corporate_Presentation.pdf

Specifically the clinical response in ITT population doesn't seem to show a dose response (slide 14). Moreover the sustained efficacy at days 10 and 28 clearly seem to favor daptomycin (slide 16).

Moreover the side effect profile, albeit mild, doesn't seem that impressive when compared to daptomycin (slide 19).

All in all, while the mechanism of action is novel and slide 21 lists the advantages 30063 has over its competitors, is the data from the current phase 2 impressive enough to land a meaningful partnership?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up